Furthermore, it has recently been shown by Tolaney and co-workers that abemaciclib plus fulvestrant is effective regardless of PIK3CA status, as PIK3CA is often mutated in HER2+ BC [123]. The gene discussed is PIK3CA; the disease is breast cancer.